Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 213

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Immune cells as targets for cardioprotection: new players and novel therapeutic opportunities

Open access
Andreadou, Ioanna, Cabrera-Fuentes, Hector A, Devaux, Yvan, Frangogiannis, Nikolaos G, Frantz, Stefan, Guzik, Tomasz, Liehn, Elisa A, Gomes, Clarissa P C, Schulz, Rainer, Hausenloy, Derek J·2019·Cardiovascular Research

Abstract

New therapies are required to reduce myocardial infarct (MI) size and prevent the onset of heart failure in patients presenting with acute myocardial infarction (AMI), one of the leading causes of death and disability globally. In this regard, the immune cell response to AMI, which comprises an initial pro-inflammatory reaction followed by an anti-inflammatory phase, contributes to final MI size and post-AMI remodelling [changes in left ventricular (LV) size and function]. The transition between these two phases is critical in this regard, with a persistent and severe pro-inflammatory reaction leading to adverse LV remodelling and increased propensity for developing heart failure. In this review article, we provide an overview of the immune cells involved in orchestrating the complex and dynamic inflammatory response to AMI—these include neutrophils, monocytes/macrophages, and emerging players such as dendritic cells, lymphocytes, pericardial lymphoid cells, endothelial cells, and cardiac fibroblasts. We discuss potential reasons for past failures of anti-inflammatory cardioprotective therapies, and highlight new treatment targets for modulating the immune cell response to AMI, as a potential therapeutic strategy to improve clinical outcomes in AMI patients. This article is part of a Cardiovascular Research Spotlight Issue entitled ‘Cardioprotection Beyond the Cardiomyocyte’, and emerged as part of the discussions of the European Union (EU)-CARDIOPROTECTION Cooperation in Science and Technology (COST) Action, CA16225.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cvr/cvz050

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 213

Metadata

Authors
Andreadou, I., Cabrera-Fuentes, H. A., Devaux, Y., Frangogiannis, N. G., Frantz, S., Guzik, T., Liehn, E. A., Gomes, C. P. C., Schulz, R., & Hausenloy, D. J.
Venue
Cardiovascular Research
Published
2019-03-02
Volume
115
Issue
7
Pages
1117-1130
ISSN
  • 0008-6363 (ISSN-L)
  • 1755-3245
OpenAlex
W2919288695
Cited by
213
References
9
FWCI
18.26
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immune cells as targets for cardioprotection: new players and novel therapeutic opportunities. https://app.cochat.ai/papers/10.1093/cvr/cvz050
The paper
Andreadou, I., Cabrera-Fuentes, H. A., Devaux, Y., Frangogiannis, N. G., Frantz, S., Guzik, T., Liehn, E. A., Gomes, C. P. C., Schulz, R., & Hausenloy, D. J. (2019). Immune cells as targets for cardioprotection: new players and novel therapeutic opportunities. Cardiovascular Research. https://doi.org/10.1093/cvr/cvz050

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.